Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: A randomized controlled trial
The Journal of Allergy and Clinical Immunology,  Clinical Article

Brown RW et al. – Pulmonary function and asthma control measures generally favored budesonide/formoterol. In this population budesonide/formoterol pressurized metered–dose inhaler (pMDI) was well tolerated over 12months, with a safety profile similar to that of budesonide; the asthma exacerbation rate was reduced by 38.5% versus budesonide.

Methods
  • This 52-week, randomized, double-blind, parallel-group, multicenter, phase 3B safety study (NCT00419952) was conducted in 742 self-reported African American patients 12 years or older with moderate-to-severe asthma previously receiving medium- to high-dose inhaled corticosteroids.
  • After 2 weeks using a 320 μg twice-daily budesonide pMDI, patients were randomized 1:1 to 320/9 μg twice-daily budesonide/formoterol pMDI or 320 μg twice-daily budesonide pMDI.

Results
  • Both treatments were well tolerated.
  • Asthma exacerbation incidence and rate (per patient-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [P = .006]; rate ratio, 0.615 [P = .002]).
  • Time to first asthma exacerbation was longer (P = .018) with budesonide/formoterol versus budesonide.
  • The most common adverse events, regardless of study drug relationship, were headache (9.5% and 7.7%), nasopharyngitis (6.9% and 8.0%), sinusitis (4.0% and 6.3%), and viral upper respiratory tract infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively.
  • Serious adverse events occurred in 12 and 15 patients, respectively; none were considered drug related.
  • No substantial or unexpected patterns of abnormalities were observed in laboratory, electrocardiographic, or Holter monitoring assessments.
  • Hospitalization caused by asthma exacerbation occurred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectively.
  • Pulmonary function and asthma control measures generally favored budesonide/formoterol.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

2 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

5 'Unsung' cells double the benefits of a new osteoporosis drug Johns Hopkins Medicine, October 7, 2014

6 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

7 Statins reverse learning disabilities caused by genetic disorder UCLA Health System, November 18, 2014

8 UCLA researchers find that drug used for another disease slows progression of Parkinson's UCLA Health System, October 10, 2014

9 Opioid overdose cause for over 100,000 emergency department visits in 2010 Lifespan, November 12, 2014

10 Semen directly impairs effectiveness of microbicides that target HIV Gladstone Institutes News, November 14, 2014

11 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

12 A new pathway discovered regulating autoimmune diseases Brigham and Women's Hospital, October 9, 2014

13 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

14 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

15 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 24, 2014    Clinical Article

16 Ripasudil: first global approval Drugs, November 21, 2014    Clinical Article

17 Effect of prasugrel in patients with asthma: results of PRINA,a randomized, double-blind, placebo-controlled, cross-over study Journal of Thrombosis and Haemostasis, November 25, 2014

18 Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide–sensitive human hypertension Hypertension, November 24, 2014    Clinical Article

19 Magnesium should be given to all children presenting to hospital with acute severe asthma Paediatric Respiratory Reviews, October 15, 2014    Clinical Article

20 Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients American Journal of Transplantation, November 17, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore